SCHEMBL4497908

SCHEMBL4497908

COC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3CNC(=O)Nc3cc(C(C)(C)C)nn3-c3cccc(OCCOC4CCCCO4)c3)c(Cl)c2=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.38
MAPK11 Q15759 2/20 0.36
ROCK2 O75116 1/20 0.36
MAPK12 P53778 1/20 0.36
STRADA Q7RTN6 1/20 0.36
MAPKAPK2 P49137 3/20 0.36
BRAF P15056 2/20 0.36
NTRK1 P04629 2/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
FYN P06241 1/20 0.36
LYN P07948 1/20 0.36
RET P07949 1/20 0.36
BCR P11274 1/20 0.36
FGFR1 P11362 1/20 0.36
EPHA1 P21709 1/20 0.36
EPHA2 P29317 1/20 0.36
ABL2 P42684 1/20 0.36
FRK P42685 1/20 0.36
MAPK9 P45984 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496970 0.96 MAPK14 (0.38) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL13678569 0.95 MAPK14 (0.36) MAPK14BRAFNTRK1MAPK9DDR2
SCHEMBL4502277 0.95 MAPK14 (0.37) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL4510417 0.94 MAPK14 (0.38) MAPK14MAPK11MAPK12NTRK1
SCHEMBL4514157 0.92 MAPK14 (0.37) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL13678568 0.92 MAPK14 (0.37) MAPK14MAPK11MAPK12BRAFMAPK9
SCHEMBL4503425 0.90 MAPK14 (0.39) MAPK14MAPK11MAPK12
SCHEMBL13678637 0.89 MAPK14 (0.42) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL4521340 0.89 MAPK14 (0.38) MAPK14MAPK11MAPK12NTRK1ABL1
SCHEMBL4500691 0.88 MAPK14 (0.45) MAPK14MAPK11ROCK2MAPK12STRADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 MAPK14 117/4885MAPK11 404/4885ROCK2 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.